S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
Positive News SentimentPositive News
NASDAQ:VTGN

Vistagen Therapeutics (VTGN) Stock Forecast, Price & News

$5.27
-0.09 (-1.68%)
(As of 09/27/2023 ET)
Compare
Today's Range
$5.16
▼
$5.61
50-Day Range
$1.68
▼
$13.05
52-Week Range
$1.62
▼
$24.71
Volume
123,620 shs
Average Volume
774,388 shs
Market Capitalization
$49.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Vistagen Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
470.3% Upside
$30.00 Price Target
Short Interest
Healthy
7.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Vistagen Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$17.96 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

711th out of 963 stocks

Pharmaceutical Preparations Industry

325th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

VTGN stock logo

About Vistagen Therapeutics (NASDAQ:VTGN) Stock

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Price History

VTGN Stock News Headlines

September 13, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
September 12, 2023 | finance.yahoo.com
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 27, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 5, 2023 | finance.yahoo.com
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
August 22, 2023 | finance.yahoo.com
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 15, 2023 | finance.yahoo.com
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript
August 12, 2023 | markets.businessinsider.com
Maxim Group Remains a Buy on VistaGen Therapeutics (VTGN)
August 11, 2023 | 247wallst.com
Commodore Capital Buys in for the Long Haul With 20% Vistagen Stake on Promising Phase 3 Data
September 27, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 11, 2023 | seekingalpha.com
VistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17M
August 11, 2023 | finance.yahoo.com
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
August 10, 2023 | finance.yahoo.com
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 8, 2023 | benzinga.com
What's Going On With VistaGen Therapeutics Stock?
August 8, 2023 | msn.com
Maxim Group Upgrades VistaGen Therapeutics (VTGN)
August 8, 2023 | finance.yahoo.com
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 8, 2023 | marketwatch.com
VistaGen Shares Explode After Successful Fasedienol Trial
August 8, 2023 | msn.com
Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
August 8, 2023 | finance.yahoo.com
Biotech Firm Pops 677% on Social Anxiety Spray Trial Success
August 8, 2023 | finance.yahoo.com
Social anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600%
August 7, 2023 | investorplace.com
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
August 7, 2023 | finance.yahoo.com
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
July 17, 2023 | finance.yahoo.com
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 13, 2023 | finance.yahoo.com
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
June 28, 2023 | finance.yahoo.com
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
June 27, 2023 | finance.yahoo.com
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
June 23, 2023 | finance.yahoo.com
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
June 21, 2023 | finance.yahoo.com
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
CUSIP
N/A
CIK
1411685
Web
www.vistagen.com
Phone
(650) 577-3600
Fax
888-482-2602
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+471.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,250,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-267.96%
Return on Assets
-174.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.86
Quick Ratio
2.86

Sales & Book Value

Annual Sales
$1.11 million
Price / Sales
44.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
3.18

Miscellaneous

Outstanding Shares
9,360,000
Free Float
9,066,000
Market Cap
$49.14 million
Optionable
Not Optionable
Beta
0.46
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Shawn K. Singh J.D. (Age 60)
    CEO & Director
    Comp: $600k
  • Mr. Reid G. Adler Esq. (Age 69)
    J.D., Chief Corp. Devel. & Legal Officer
    Comp: $371.88k
  • Ms. Cynthia Lynn Anderson CPA (Age 54)
    Chief Financial Officer
  • Mr. Joshua Prince M.B.A.
    Sr. VP of Bus. Operations
  • Mr. Mark Adrian McPartland (Age 57)
    Sr. VP of Investor Relations
  • Ms. Trisha Fitzmaurice
    Sr. VP of HR
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Sr. VP of Devel. Operations
  • Dr. Mark J. Ginski Ph.D. (Age 51)
    Sr. VP and Head of Chemistry, Manufacturing & Controls
  • Mr. Mark Flather
    VP of Corp. Strategy & Capital Markets
  • Dr. Erik Berglund M.D.
    Ph.D., Sr. VP of Global Regulatory Affairs & Pharmacovigilance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VTGN Stock - Frequently Asked Questions

Should I buy or sell Vistagen Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTGN shares.
View VTGN analyst ratings or view top-rated stocks.

What is Vistagen Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month price objectives for Vistagen Therapeutics' shares. Their VTGN share price forecasts range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests a possible upside of 471.4% from the stock's current price.
View analysts price targets for VTGN or view top-rated stocks among Wall Street analysts.

How have VTGN shares performed in 2023?

Vistagen Therapeutics' stock was trading at $3.09 at the start of the year. Since then, VTGN shares have increased by 69.9% and is now trading at $5.25.
View the best growth stocks for 2023 here.

Are investors shorting Vistagen Therapeutics?

Vistagen Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 715,100 shares, a decrease of 31.9% from the August 31st total of 1,050,000 shares. Based on an average daily volume of 1,800,000 shares, the days-to-cover ratio is currently 0.4 days. Currently, 7.7% of the company's shares are sold short.
View Vistagen Therapeutics' Short Interest.

When is Vistagen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VTGN earnings forecast.

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.94) EPS for the quarter. The business had revenue of $0.18 million for the quarter.

When did Vistagen Therapeutics' stock split?

Shares of Vistagen Therapeutics reverse split on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.32%), Geode Capital Management LLC (0.72%), Goldman Sachs Group Inc. (0.61%), Y Intercept Hong Kong Ltd (0.51%), State Street Corp (0.27%) and Citadel Advisors LLC (0.21%). Insiders that own company stock include Commodore Capital Lp, H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $5.25.

How much money does Vistagen Therapeutics make?

Vistagen Therapeutics (NASDAQ:VTGN) has a market capitalization of $49.14 million and generates $1.11 million in revenue each year.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -